glp 1 and pet scan Advances in Endocrine Tumor Imaging Targeting CXCR4 GLP-1 Glucagon-like Peptide-1 Receptor as Emerging

Weight loss typically slows after the first several months on GLP-1 medications

doi: 10.7759/cureus.33509

It could thus be assumed that in a state of high cardiovascular risk, the body tries to limit disease progression by increasing the secretion of the protective agent GLP-1

Fat tissue produces an enzyme called aromatase, which converts testosterone into estrogen.The more fat you carry, the more aromatization occurs, which lowers available testosterone and raises estrogen

Summary: GLP-1 receptor agonists are prescription medications that may support weight management during perimenopause by suppressing appetite and delaying gastric emptying, but they are not specifically indicated for hormonal changes and require strict NHS eligibility criteria

doi: 10.1172/jci.insight.140711 49 MukherjeeAPakhchanianHRaikerRSinghSChatterjeeA